Nexalis Therapeutics Limited (ASX:NX1)

Australia flag Australia · Delayed Price · Currency is AUD
0.0210
0.00 (0.00%)
At close: Mar 9, 2026
-44.74%
Market Cap 5.31M
Revenue (ttm) 761.96K
Net Income (ttm) -1.83M
Shares Out 253.04M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 367
Average Volume 294,892
Open 0.0210
Previous Close 0.0210
Day's Range 0.0210 - 0.0210
52-Week Range 0.0180 - 0.0480
Beta -0.24
RSI 41.77
Earnings Date Feb 27, 2026

About Nexalis Therapeutics

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol NX1
Full Company Profile

Financial Performance

In 2025, Nexalis Therapeutics's revenue was 767,691, an increase of 91.06% compared to the previous year's 401,811. Losses were -1.83 million, 51.3% more than in 2024.

Financial Statements

News

There is no news available yet.